@article{JTD21374,
author = {Hui Shi and Feng Yu and Yinting Mao and Qianqian Ju and Yingcheng Wu and Wen Bai and Peiwen Wang and Ran Xu and Maorong Jiang and Jiahai Shi},
title = {EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {5},
year = {2018},
keywords = {},
abstract = {Background: It is urgent to explore an effective potential therapeutic strategy for ESCC. In recent years, cell-based cancer immunotherapy has become a potentially close for carcinoma therapy. Chimeric antigen receptor (CAR) T cell technology is a kind of adoptive cell therapy technique which has been developed rapidly. We sought to obtain EphA2.CAR-T cell and revealed the ability of EphA2.CAR-T cells to kill esophageal squamous cell carcinoma (ESCC) cells in vitro.
Methods: Firstly, the expression and location of EphA2 in ESCC tissues and cells was tested by immunohistochemistry staining and Western blot. Secondly, the second generation of EphA2.CAR was constructed via molecular biology technology, and transduced into T cells to obtain the EphA2.CAR-T cell. The transduction efficacies were assessed using flow cytometry (FCM). Thirdly, the effect of cell killing of EphA2.CAR-T cell on ESCC cells in vitro was detected by co-culture experiments. The productions of cytokines (TNF-α and IFN-γ) by EphA2.CAR-T cell after co-culture with ESCC cells were analyzed by ELISA assay.
Results: The expression of EphA2 was significantly upregulated in ESCC tissues and cells (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/21374}
}